Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Free Cash Flow (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Free Cash Flow for 11 consecutive years, with -$61.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 20.12% to -$61.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$336.2 million, a 7.64% increase, with the full-year FY2025 number at -$336.2 million, up 7.64% from a year prior.
  • Free Cash Flow was -$61.9 million for Q4 2025 at Iovance Biotherapeutics, up from -$89.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$61.3 million in Q3 2024 to a low of -$126.4 million in Q1 2024.
  • A 3-year average of -$90.4 million and a median of -$88.6 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 30.12% in 2024, then plummeted 46.17% in 2025.
  • Iovance Biotherapeutics' Free Cash Flow stood at -$87.5 million in 2023, then increased by 11.47% to -$77.5 million in 2024, then rose by 20.12% to -$61.9 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Free Cash Flow are -$61.9 million (Q4 2025), -$89.5 million (Q3 2025), and -$74.9 million (Q2 2025).